Lingohr Asset Management GmbH Makes New $589,000 Investment in Pfizer Inc. $PFE

Lingohr Asset Management GmbH purchased a new stake in Pfizer Inc. (NYSE:PFE) during the third quarter, HoldingsChannel reports. The institutional investor purchased 23,100 shares of the biopharmaceutical company’s stock, valued at approximately $589,000.

Several other institutional investors and hedge funds also recently modified their holdings of PFE. Citizens National Bank Trust Department grew its stake in shares of Pfizer by 0.9% during the 2nd quarter. Citizens National Bank Trust Department now owns 46,103 shares of the biopharmaceutical company’s stock worth $1,118,000 after acquiring an additional 395 shares in the last quarter. Peak Asset Management LLC boosted its holdings in Pfizer by 1.4% during the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after purchasing an additional 402 shares during the last quarter. Community Bank & Trust Waco Texas boosted its holdings in Pfizer by 0.6% during the third quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock worth $1,703,000 after purchasing an additional 412 shares during the last quarter. Able Wealth Management LLC grew its position in Pfizer by 2.0% in the second quarter. Able Wealth Management LLC now owns 21,128 shares of the biopharmaceutical company’s stock valued at $512,000 after purchasing an additional 413 shares in the last quarter. Finally, CVA Family Office LLC increased its stake in Pfizer by 3.3% in the 3rd quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock valued at $329,000 after buying an additional 413 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Sanford C. Bernstein restated a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a report on Friday, October 31st. Morgan Stanley reduced their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research report on Friday, December 12th. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Zacks Research cut Pfizer from a “hold” rating to a “strong sell” rating in a research note on Monday, January 26th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average target price of $28.06.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla is doubling down on oncology with a roughly $23 billion post?COVID investment plan, positioning Pfizer as a major growth bet on cancer therapies — a strategic pivot investors see as a multi?year revenue driver. ‘We’ll save the world from cancer’: Inside Pfizer CEO’s $23 billion post?COVID bet on oncology
• Positive Sentiment: Pfizer struck a non?exclusive licensing agreement to access Novavax’s Matrix?M adjuvant technology (reported value ~$530M), which could boost future vaccine efficacy and pipeline value. Pfizer Inks $530M Deal for Novavax Matrix?M Adjuvant Technology
• Positive Sentiment: A bullish technical/forecast note projects upside toward ~$36.16, which can attract momentum and speculative buying. PFIZER Stock Holds Near $25.86 as Forecast Targets $36.16 Upside
• Neutral Sentiment: Pfizer is due to report Q4 and full?year 2025 results before the market opens Feb. 3; consensus Q4 estimates cited are ~$16.9B sales and $0.57 EPS — the upcoming print is the near?term catalyst. Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings?
• Neutral Sentiment: Zacks and other outlets report heightened retail/investor attention on PFE and provide deeper metric estimates ahead of earnings — increased search/coverage can amplify moves on the print. Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
• Neutral Sentiment: Background pieces (portfolio company lists, Wall Street metric breakdowns) add context but are unlikely to move the stock materially on their own. 7 Companies Owned by Pfizer
• Negative Sentiment: Critical commentary warns of valuation and execution risks (Seeking Alpha: “Buyer Beware”) and highlights that risks may outweigh near?term rewards, which can pressure sentiment. Pfizer: Buyer Beware, The Risk Outweighs The Reward
• Negative Sentiment: Media coverage of past management tactics (CEO comments on extreme COVID-era measures) and notes that PFE has recently underperformed peers may feed governance/PR concerns and short?term selling. Pfizer CEO says he used ‘emotional blackmail’ to get employees to achieve impossible goals during COVID-19 Pfizer Inc. stock underperforms Wednesday when compared to competitors

Pfizer Price Performance

NYSE:PFE opened at $26.43 on Friday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.69. The firm has a market capitalization of $150.24 billion, a price-to-earnings ratio of 15.36 and a beta of 0.47. The stock’s 50 day moving average price is $25.52 and its two-hundred day moving average price is $25.03. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. The ex-dividend date is Friday, January 23rd. Pfizer’s payout ratio is currently 100.00%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.